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Letters to the Editormore than 1000 mL of total discharge
from the chest drains. The secondary
endpoint was a composite of cardio-
vascular death, myocardial infarction,
and repeat revascularization. All pa-
tients discontinued aspirin 7 days
before surgery. The night before sur-
gery, they received either 300 mg of
aspirin or placebo. Starting 6 hours
postoperatively, a daily 300 mg dose
of aspirin was continued in all patients.
The study results in the aspirin group
revealed a significant increase in post-
operative bleeding and a long-term
hazard decrease of nonfatal coronary
events (myocardial infarction and
repeat revascularization). We wish to
point out a few confounders and cur-
rent antiplatelet therapy issues that
we believe readers should consider
when interpreting the study results.
As acknowledgedby the authors, the
contemporary cardiac surgery practice
encourages aspirin administration up
until surgery.Wenoted that one quarter
of the patients had undergone percuta-
neous coronary intervention 4 months
(range, 2-10) before surgery. The rec-
ommendation guidelines for antiplate-
let therapy after percutaneous coronary
intervention suggest that most of those
patients were receiving dual antiplate-
let therapy after undergoing that proce-
dure.2 The authors do not mention if
the patients were taking thienopyri-
dines before surgery. If they were tak-
ing theinopyridines, how many days
before surgery were they told to stop
taking them?We consider this of great
importance for the study end points be-
cause theinopyridines have a much
greater influence on postoperative
bleeding than aspirin.
A major confounder in the present
study we consider to be the lack of
platelet response to aspirin quantifica-
tion. Recent evidence has shown sig-
nificant individual variability in the
response to aspirin and its link to
outcomes.3 The terms ‘‘aspirin resis-
tance’’ and ‘‘high on-treatment resid-
ual platelet reactivity’’ have been
introduced. Accordingly, the reported
prevalence of ‘‘aspirin resistance’’The Journalvaries widely from less than 1% to
61%.4 Platelet function tests, such as
whole blood platelet aggregometry
and impedance aggregometry, quantify
the aspirin response. Just recently, we
published a study addressing the prev-
alence of ‘‘aspirin resistance’’ using
a point-of-care platelet function ana-
lyzer in a coronary artery bypass graft-
ing population.5 According to the
platelet function results, individually
tailored dose-dependent aspirin ther-
apy could be recommended to reduce
adverse effects (eg, bleeding) and pre-
serve the beneficial effects. Continuous
aspirin therapy up until surgery could
prevent preoperative ischemic events,
particularly in the residual platelet
reactivity population. Preoperative dis-
continuation could be advised for those
with a pronounced response to aspirin.
Although it is most likely true that
patients taking preoperative aspirin
bleed more than the patients who
discontinued aspirin and that the inci-
dence of the long-term composite of
cardiovascular death, myocardial in-
farction, and repeat revascularization
could be reduced, it is important to
keep in perspective the limitations of
this study. Additional research and
implementation of platelet function
tests in everyday clinical practice will
only improve patient management
and, hopefully, reduce morbidity and
mortality.
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We would like to thank Kopjar and
colleagues1 for their interest in our
study and comments on our report.
Our study definitely shows that preop-
erative aspirin use increases postoper-
ative bleeding but simultaneously
provides some data to support the be-
lief that it might be acceptable because
of the improved long-term outcome.2
As rightly raised by Kopjar and col-
leagues,1 aspirin resistance constitutes
a major issue in modern cardiology
and cardiac surgery. Its effect on clin-
ical outcome has been established in
many studies.3 The number of aspirin
nonresponders and weak responders
after coronary artery bypass surgery
is estimated to be quite high.4 That
we did not assess platelet function
could, therefore, be considered amajor
limitation of the study. However, the
beauty of a randomized design is
that, by definition, it equalizes the
confounders in both treatment arms.
It is even more so when a study is dou-
ble blinded and placebo controlled, as
ours was. Thus, we believe the results
of our study are sound and valid, even
if the ‘‘aspirin resistance’’ was not
assessed.
In addition, the increased bleeding
incidence in patients receiving aspirin
preoperatively in our study hasy c Volume 144, Number 5 1275
Letters to the Editorconfirmed that aspirin was effective in
at least some of them. In fact, resis-
tance to aspirin in some patients might
have actually hindered the real mean
difference in bleeding and reduced
the apparent long-term benefit of
preoperative aspirin administration
among the responders.
The separate unresolved issue re-
mains the choice of platelet function
assay to use in clinical practice and
clinical trials. Let us finish by citing
the conclusions of a unique report by
Lordkipanidze and colleagues,5 who
compared in the same population 6
major different methods used to test
platelet function: ‘‘. conclusions
drawn could be highly dependent on
the test used and results from various
assays are clearly not interchangeable.
Hence, the clinical usefulness of the
different platelet function tests to de-
tect appropriately aspirin resistant
patients remains uncertain.’’
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OF THE BRONCHOSCOPIST
To the Editor:
We read with interest the report
‘‘Prospective study of endobronchial
ultrasound-guided transbronchial nee-
dle aspiration of lymph nodes versus
transbronchial lung biopsy of lung tis-
sue for diagnosis of sarcoidosis’’ by
Oki and colleagues,1 which appeared
in the June issue of the Journal.While
congratulating them for their effort in
clarifying this controversial and rele-
vant topic, we want to share some sig-
nificant concerns we had as we read
their report.
Our first concern pertains to the se-
lection of patients. To be valid, a diag-
nostic study should include patients
with diagnostic uncertainty. This is,
in part, because patients with an obvi-
ous diagnosis do not need diagnostic
tests. Although the authors included
patients with suspected stage I or II
sarcoidosis (excluding those with
biopsy proven disease), it is unclear
whether they included consecutive
patients or not. If they did not include
consecutive patients by filtering out
some individuals, it becomes crucial
to know how many and why these pa-
tients were excluded. We believe their
study could potentially have a spec-
trum bias, overestimating the diagnos-
tic power of the test by including
target-positive patients.2
Other potential problems in the
validity of the study by Oki and col-
leagues1 could also be inflating the
results. One of these is that the tests
being studied were a part of the refer-
ence standard.3 That explains why the
specificities for both tests were
100%. All patients who had epitheli-
oid cell granulomas were considered
to have sarcoidosis using the clinical,
radiologic, and pathologic criteria
used as the reference standard. Al-
though it is true a single reference
standard is not available for sarcoido-
sis and a multidisciplinary meeting is
recommended, a blind assessment
from the adjudicators of outcome
would have been preferred. It is notCardiovascular Surgery c November 20stated in their report who adjudicated
the diagnosis.
The lack of randomization regard-
ing the order of the tests also raises
a concern. This was acknowledged
by the authors in their discussion.
We can think of a few potential biases
from performing endobronchial ultra-
sonography first in every patient, and
there might be many other biases
that we have not considered. Random-
izing the order of the tests would have
been a great addition to the study
protocol and would have decreased
the chances of bias toward 1 proce-
dure or the other. In addition, before
the era of chest computed tomogra-
phy, when mainly chest radiography
was used to classify a patient as hav-
ing stage I, transbronchial biopsy
had a greater diagnostic yield.4 Cur-
rently, with high-resolution computed
tomography of the chest widely avail-
able, the yield of transbronchial
biopsy is understandably lower.5
As a final comment, we have to
discuss the applicability of the data.
Most patients included in the trial
had stage I sarcoidosis. Physicians
reading their report might leave with
the message that all patients with sus-
pected stage I sarcoidosis should
undergo biopsy. We believe that be-
cause a bronchoscopy can be done
does not mean it should be done.
The decision to establish the diagnosis
of sarcoidosis should remain in the
domain of the clinician caring for the
patient and not the bronchoscopist.
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